Association between bone mineral density and serum lipids in men [6]

JAMA

Volumn 286, Issue 7, 2001, Pages 791-792

  Adami, S ^a   Braga, V ^a   Gatti, D ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ADULT; AGE; AGED; BODY MASS; BONE DENSITY; BONE MASS; BONE MINERALIZATION; CALCIUM INTAKE; CHOLESTEROL BLOOD LEVEL; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; GENETIC ASSOCIATION; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; HYPERTRIGLYCERIDEMIA; INCIDENCE; LETTER; LIPID BLOOD LEVEL; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SMOKING HABIT;

EID: 0035880303     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.286.7.791     Document Type: Letter

References (7)

1. Inhibitors of hydroxymethylglutarylcoenzyme A reductase and the risk of fracture among older women
2. HMG-CoA reductase inhibitors and the risk of hip fracture in elderly patients
3. HMG-CoA reductase inhibitors and the risk of fractures
4. Use of statins and risk of fractures
5. Effect of pravastatin on frequency of fracture in the LIPID study: Secondary analysis of a randomised controlled trial
6. Statin drugs and the risk of fracture
7. Relationship between VDR (Bsml and Fokl), COLIA1 and CTR polymorphisms with bone mass, bone turnover markers and sex hormones in men